Home LiteratureArticle Details
PMID: 19235596 Published · ppublish English Clinical Trial, Phase II Journal Article Research Support, N.I.H., Intramural

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Cancer investigation ·Vol. 27 ·No. 2 ·2009-02-00 ·Pages 221-6

Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL

Abstract

ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.

MeSH Terms
Adult Aged Alendronate/adverse effects Angiogenesis Inhibitors/therapeutic use Diphosphonates/adverse effects Humans Ibandronic Acid Incidence Jaw Diseases/chemically induced,epidemiology Male Middle Aged Neoplasm Metastasis Osteonecrosis/chemically induced,epidemiology Prostatic Neoplasms/complications,drug therapy,pathology
Chemicals
Angiogenesis Inhibitors Diphosphonates Ibandronic Acid Alendronate
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Aragon-Ching Jeanny B
Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. chingj@mail.nih.gov
Ning Yang-Min
Chen Clara C
Latham Lea
Guadagnini Jean-Pierre
Gulley James L
Arlen Philip M
Wright John J
Parnes Howard
Figg William D
Dahut William L
References (31)
31 references, click to expand
  1. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 PMID: 12359855
  2. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75 PMID: 16243172
  3. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
    Br J Haematol. 2006 Sep;134(6):620-3 PMID: 16889620
  4. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids.
    Clin Orthop Relat Res. 1986 Mar;(204):150-3 PMID: 3006960
  5. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
    J Bone Miner Res. 1997 Oct;12(10):1700-7 PMID: 9333131
  6. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.
    J Bone Miner Metab. 2005;23 Suppl:36-42 PMID: 15984412
  7. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Acta Oncol. 2007;46(5):664-8 PMID: 17562443
  8. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.
    Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3256-62 PMID: 18089719
  9. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
    J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 PMID: 12183663
  10. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31 PMID: 17577497
  11. Osteonecrosis of the jaw and bisphosphonates.
    N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 PMID: 16003837
  12. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
    Ann Oncol. 2008 Mar;19(3):420-32 PMID: 17906299
  13. Osteonecrosis after chemotherapy.
    Lancet. 1978 Jun 17;1(8077):1316 PMID: 78083
  14. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
    Med Oral Patol Oral Cir Bucal. 2007 Aug 01;12(4):E336-40 PMID: 17664922
  15. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
    J Oral Maxillofac Surg. 2004 May;62(5):527-34 PMID: 15122554
  16. Osteonecrosis of the jaws: a complication of cancer chemotherapy.
    Head Neck Surg. 1982 Jan-Feb;4(3):251-3 PMID: 6896046
  17. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature.
    Eur J Intern Med. 2007 Sep;18(5):417-22 PMID: 17693231
  18. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.
    Crit Rev Oncol Hematol. 2007 May;62(2):148-52 PMID: 17336086
  19. Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
    Acta Oncol. 2006;45(2):216-7 PMID: 16546871
  20. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 PMID: 12966493
  21. Zoledronic acid and angiogenesis.
    Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6850; author reply 6850-1 PMID: 18006788
  22. Summary of ASBMR Task Force on ONJ.
    J Musculoskelet Neuronal Interact. 2007 Oct-Dec;7(4):354-5 PMID: 18094510
  23. Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution.
    Hell J Nucl Med. 2007 Sep-Dec;10(3):177-80 PMID: 18084661
  24. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
    Nat Clin Pract Oncol. 2006 Jun;3(6):325-38 PMID: 16757970
  25. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
    Dentomaxillofac Radiol. 2006 Jul;35(4):236-43 PMID: 16798918
  26. Osteonecrosis of the jaws associated with cancer chemotherapy.
    J Oral Maxillofac Surg. 2003 Sep;61(9):1104-7 PMID: 12966490
  27. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    Med Oral Patol Oral Cir Bucal. 2007 Sep 01;12(5):E351-6 PMID: 17767097
  28. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
    Cancer Res. 2002 Nov 15;62(22):6538-44 PMID: 12438248
  29. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.
    Ann Intern Med. 2006 May 16;144(10):753-61 PMID: 16702591
  30. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    J Clin Oncol. 2005 Dec 1;23(34):8580-7 PMID: 16314620
  31. Osteonecrosis of the jaw and bisphosphonates.
    N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 PMID: 16000365
Article Info
Journal
Cancer investigation
Abbr.
Cancer Invest
ISSN
1532-4192
DOI
10.1080/07357900802208608
Email
chingj@mail.nih.gov
Published
2009-02-00
Pages
221-6
Language
English
Region
England
NLM ID
8307154
PMCID
PMC2648132
Subset
IM
Grants
Intramural NIH HHS · NIH0011802535 · United States
External Links
PubMed source DOI: 10.1080/07357900802208608 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2